Challenges in Oncology

Morkas, Muffaddal; Fleming, Donald R.; Hahl, Michael J.

doi:10.1200/jco.2002.20.3.867

Cited by 25 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathophysiological mechanisms remain obscure, however, some of the proposed theories include a cytotoxic chemotherapy-induced activation of memory-type inflammatory cells (that survived radiotherapy) [65, 68], an idiosyncratic hypersensitivity reaction akin to fixed drug eruption (FDE), and a deficiency in the individual’s nutritional status leading to an impairment in endogenous scavenging activity [62]. …”

Section: Recall Phenomenamentioning

confidence: 99%

Dermatological adverse events with taxane chemotherapy

Sibaud

LeBoeuf

Roché

et al. 2016

European Journal of Dermatology

177

179

View full text Add to dashboard Cite

Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents. With an increase in the occurrence of cutaneous AEs during treatment with novel targeted and immunological therapies when used in combination with taxanes, a thorough understanding of reactions attributable to this class is imperative. Moreover, identification and management of dermatological AEs is critical for maintaining the quality of life in cancer patients and for minimizing dose modifications of their antineoplastic regimen. This analysis represents a systematic review of the dermatological conditions reported with the use of these drugs, complemented by experience at comprehensive cancer centres. The conditions reported herein include skin, hair, and nail toxicities. Lastly, we describe the dermatological data available for the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.

show abstract

Section: Recall Phenomenamentioning

confidence: 99%

Dermatological adverse events with taxane chemotherapy

Sibaud

LeBoeuf

Roché

et al. 2016

European Journal of Dermatology

177

179

View full text Add to dashboard Cite

show abstract

A case of radiation recall mucositis associated with docetaxel

et al. 2004

View full text Add to dashboard Cite

Background. Radiation recall reactions, in particular dermatitis, are well documented in the literature. However, radiation recall mucositis is a rare clinical phenomenon.Methods. We report a case of a 45-year-old man diagnosed with squamous cell carcinoma of the base of tongue. He was treated with surgery followed by chemotherapy and radiation therapy. Several months after completing treatment, he had a recurrence develop outside of the previously irradiated field. He was offered radiation therapy concurrent with docetaxel as salvage therapy.Results. During salvage therapy, acute recall mucositis developed corresponding to his previously irradiated fields. His chemotherapy with docetaxel was withheld, and his symptoms rapidly improved.Conclusions. This case describes radiation recall mucositis associated with docetaxel, a rare but potentially serious clinical situation. Given the potential severity of the reaction and increasing use of docetaxel as second-line treatment of recurrent head and neck cancers, it is important to be aware of this phenomenon. B

show abstract

Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes

Larrosa,

Mico,

Ramos

et al. 2024

Pediatric Blood & Cancer

View full text Add to dashboard Cite

IntroductionRadiation recall reaction (RRR) is a rare inflammatory reaction developing in a previously irradiated field after a triggering agent. In pediatric patients, it is poorly understood and deficiently studied. Gemcitabine–docetaxel (G/D) in childhood cancer is mainly used as a salvage regimen for sarcomas. We aim to describe RRR triggered by G/D in children.Patients and methodsRetrospective review of 21 patients receiving G/D along with radiotherapy at two hospitals from 2010 until 2022. RRR was considered as any toxicity occurring after G/D administration in a previously irradiated field. RRR features were described. Fisher's and Mann–Whitney tests were utilized to analyze the risk factors involved.ResultsSixteen episodes of RRR developed in 16 (76.2%) patients. RRR mainly involved deep layers of the skin (58%) and occurred predominantly after two G/D cycles. The mean time between radiotherapy and chemotherapy was 28.5 days (0–1359 days), and the mean radiation volume 391 mL (157–1810 mL) for RRR. RRR treatment was mainly systemic steroids, with partial responses in six of 11 (58%) patients. Re‐exposure to G/D was associated with a high rate of recurrence in nine of 15 (56.2%), prompting drug discontinuation. The major risk factors for RRR after G/D include, without statistical significance, a larger volume of the irradiated field and a shorter interval between chemotherapy and radiotherapy.ConclusionsThe incidence of RRR after G/D in the pediatric population is higher than previously reported. Drug re‐exposure is usually followed by recurrence. Higher irradiated volumes and a shorter time to the start of chemotherapy could be related with an increased risk of RRR.

show abstract

Challenges in Oncology

Cited by 25 publications

References 15 publications

Dermatological adverse events with taxane chemotherapy

Dermatological adverse events with taxane chemotherapy

A case of radiation recall mucositis associated with docetaxel

Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes

Contact Info

Product

Resources

About